PMID- 27477415
OWN - NLM
STAT- MEDLINE
DCOM- 20170322
LR  - 20181202
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 55
IP  - 15
DP  - 2016
TI  - Rituximab-induced Acute Thrombocytopenia in High Tumor Burden Follicular 
      Lymphoma.
PG  - 2061-4
LID - 10.2169/internalmedicine.55.6140 [doi]
AB  - Rituximab-induced acute thrombocytopenia (RIAT), a rare complication of rituximab 
      administration, has not yet been described in follicular lymphoma (FL). A 
      65-year-old man received rituximab for the treatment of high tumor burden 
      follicular lymphoma in the leukemic phase. The next day, his platelet count 
      abruptly dropped from 85,000 to 5,000/muL, which spontaneously recovered in a few 
      days without specific treatment. We speculate that the occurrence of 
      infusion-related cytokine release syndrome in rituximab-sensitive high tumor 
      burden FL contributed to the development of RIAT. Frequent monitoring of the 
      platelet count is advisable for select patients considered to be at a high risk 
      for RIAT.
FAU - Ureshino, Hiroshi
AU  - Ureshino H
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Japan.
FAU - Nishioka, Atsujiro
AU  - Nishioka A
FAU - Kojima, Kensuke
AU  - Kojima K
FAU - Suzuki, Motoaki
AU  - Suzuki M
FAU - Kizuka, Haruna
AU  - Kizuka H
FAU - Sano, Haruhiko
AU  - Sano H
FAU - Shindo, Takero
AU  - Shindo T
FAU - Kubota, Yasushi
AU  - Kubota Y
FAU - Ando, Toshihiko
AU  - Ando T
FAU - Kimura, Shinya
AU  - Kimura S
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20160801
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Antineoplastic Agents)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage/*adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Humans
MH  - Lymphoma, Follicular/drug therapy
MH  - Male
MH  - Platelet Count
MH  - Rituximab/administration & dosage/*adverse effects
MH  - Thrombocytopenia/*chemically induced/diagnosis/therapy
MH  - Treatment Outcome
MH  - *Tumor Burden
EDAT- 2016/08/02 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/08/02 06:00
PHST- 2016/08/02 06:00 [entrez]
PHST- 2016/08/02 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - 10.2169/internalmedicine.55.6140 [doi]
PST - ppublish
SO  - Intern Med. 2016;55(15):2061-4. doi: 10.2169/internalmedicine.55.6140. Epub 2016 
      Aug 1.